Positive Opinion, Program Honorees, Positive Medical Results, and Investor Day - Research Report on Bristol-Myers Squibb, Ariad Pharmaceuticals, Dyax, Ironwood Pharmaceuticals, and Immunomedics

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, November 27, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Bristol-Myers Squibb Company (NYSE: BMY), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Dyax Corp. (NASDAQ: DYAX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), and Immunomedics Inc. (NASDAQ: IMMU). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Bristol-Myers Squibb Company Research Report

On November 22, 2013, Bristol-Myers Squibb Company (Bristol-Myers Squibb), together with AstraZeneca, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the approval of Xigduo™ (dapagliflozin and metformin hydrochloride) for 18 years and older adults with type 2 diabetes mellitus as an adjunct to diet and exercise for improving glycaemic control in patients inadequately controlled on their current metformin-based treatment regimen or who are currently being treated with the combination of dapagliflozin and metformin as separate tablets. Bristol-Myers Squibb informed that CHMP's positive opinion will now be reviewed by the European Commission, which holds the authority to approve medicines for the EU. The Company added that the final decision will be applicable to all 28 EU member countries plus Iceland and Norway. The Full Research Report on Bristol-Myers Squibb Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/81a9_BMY

Ariad Pharmaceuticals Inc. Research Report

On November 22, 2013, Ariad Pharmaceuticals Inc. (Ariad Pharmaceuticals) announced the adoption of a positive opinion by the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) on the continued availability of the Company's Iclusig (ponatinib) in the EU for use in patients in its authorized indications. The Company added that subsequent to its review of updated clinical-trial data on Iclusig, the CHMP made recommendations on measures to help reduce the risk of occlusive vascular events in patients taking Iclusig. Jonathan E. Dickinson, General Manager, ARIAD Pharmaceuticals commented, "The conclusions reached by the CHMP, which were announced today, confirm a positive benefit-risk assessment for Iclusig after considering the most recent safety information." The Full Research Report on Ariad Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/161c_ARIA

Dyax Corp. Research Report

On November 21, 2013, Dyax Corp. (Dyax) announced five HAE Allies honorees selected for recognition by the HAE Allies program for their contributions in supporting individuals with hereditary angioedema (HAE) to live life to the fullest. Dyax stated that the HAE Allies program hopes to highlight the value of support for those living with hereditary angioedema, a potentially life-threatening condition characterized by spontaneous episodes of swelling in the face, feet, hands, throat and abdomen, by drawing from the inspiring stories of individuals nationwide. The Company informed that honorees were selected by a multi-disciplinary council of HAE experts organized by Dyax, which develops and markets KALBITOR (ecallantide) for the treatment of sudden attacks of HAE in patients 16 years of age and older. Gustav Christensen, President and CEO of Dyax stated, "A support network is essential to those living with HAE. These honorees truly exemplify the meaningful difference individuals can make for someone struggling with a rare disease." The Full Research Report on Dyax Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/58ae_DYAX

Ironwood Pharmaceuticals Inc. Research Report

On November 21, 2013, Ironwood Pharmaceuticals Inc. (Ironwood) announced that it will hold its  Investor Day on December 12, 2013, starting at 8:30 a.m. ET in New York City. The Company stated that its leadership team members will provide an in-depth review of the Company, including progress and insights regarding its research, development and commercial efforts. Ironwood added that the live webcast of the event can be accessed via Investors section of the Company's website, and replay of the same will also be available for 90 days at the same location. The Full Research Report on Ironwood Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/dbc4_IRWD

Immunomedics Inc. Research Report

On November 8, 2013, Immunomedics Inc. (Immunomedics) announced that some patients who had failed prior therapy with irinotecan or camptosar, both topoisomerase-1 inhibitors, responded to IMMU-132, the Company's lead antibody-drug conjugate (ADC) in clinical development for the treatment of patients with solid cancers. According to the release, Dr. Allyson Ocean of Weill-Cornell Medical College, New York, was invited by the Program Chairs to present the updated results at the Symposium, which is jointly organized by the Mount Sinai School of Medicine and the Chemotherapy Foundation, in collaboration with The Tisch Cancer Institute. The Company stated that out of the 18 patients who responded to IMMU-132, 8 had failed prior therapies with irinotecan or camptosar. Immunomedics added that since irinotecan is the parent of SN-38, the Company's drug of choice in IMMU-132, it postulates that the increased amount of SN-38 delivered to the tumors by IMMU-132 overcomes the tumor's resistance to this class of drugs. Immunomedics informed that the study was supported in part by Award Number R43CA171388 from the National Cancer Institute. The Full Research Report on Immunomedics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/c20d_IMMU

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  5. For any urgent concerns or inquiries, please contact us at [email protected].
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

www.AnalystsCorner.com

SOURCE Analysts' Corner

Suggested Articles

Novartis said it plans to use the complete response rate data for a U.S. filing in follicular lymphoma in 2021.

Sen. Elizabeth Warren asked the SEC to probe Kodak trades made before the Trump administration unveiled their drug supply deal—and $765M in funding.

Amarin's wild 2020 ride continues with plans to launch its cardiovascular med Vascepa in Europe without a bigger marketing partner.